SJ
Sushma Jha
About Sushma Jha
Data last updated:
Sushma Jha has 7 years in corporate governance. Holds Director role. Currently with 2 companies, including Novanice Pharmaceutical Private Limited and Entares Pharmaceutical Private Limited. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Entares Pharmaceutical Private Limited at ₹8,840 (FY 2024).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 06 Aug 2019 | 2019 | ₹8,840 (FY 2024) | Active | |
| Director | 28 Oct 2025 | 2025 | – | Active |
Previous companies
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Sushma Jha
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sushma Jha
Sushma Jha has 7 years in corporate governance. Holds Director role. Currently with 2 companies, including Novanice Pharmaceutical Private Limited and Entares Pharmaceutical Private Limited. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Entares Pharmaceutical Private Limited at ₹8,840 (FY 2024).
Sushma Jha is associated with 2 companies as Director, including Entares Pharmaceutical Private Limited (₹8,840), Novanice Pharmaceutical Private Limited.
Sushma Jha has expertise in General Business.
Sushma Jha has 7 years in corporate governance.
By reported revenue, the largest current company of Sushma Jha is Entares Pharmaceutical Private Limited, with revenue of ₹8,840 (FY 2024).
Sushma Jha currently holds positions at 2 companies: Entares Pharmaceutical Private Limited (₹8,840), Novanice Pharmaceutical Private Limited.